SecBot SecBot
SECBOTREPLAY Home › Report › NAMS

NAMS · NewAmsterdam Pharma reported Q2 2026 results alongside the announcement…

NewAmsterdam Pharma Co N.V. · 8-K filed Aug 5, 2026 at 07:08 ET

At the news

BULLISHIMPACT 7/10

8-K filed Aug 5, 2026 at 07:08 ET

NewAmsterdam Pharma reported Q2 2026 results alongside the announcement that the CHMP has adopted a positive opinion recommending marketing authorization for obicetrapib (Ubeslo) and obicetrapib/ezetimibe FDC (Evlarco) in Europe, the most significant catalyst to date. Net loss widened to $64.1M from $17.4M a year ago on higher R&D costs and non-recurring Menarini milestone revenue in the prior-year period, but cash remains ample at $678.3M.

  • CHMP positive opinion for obicetrapib 10 mg and FDC with ezetimibe; European Commission decision expected in 2H26
  • Cash, cash equivalents and marketable securities of $678.3M at June 30, 2026
  • Net loss of $64.1M in Q2 2026 vs $17.4M in Q2 2025
  • Revenue of $3.7M vs $19.1M prior year (prior-year included $16.1M development cost contribution from Menarini)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access